Xeris Biopharma Holdings, Inc. (XERS) insider trading.
In Q3 2026, insiders at Xeris Biopharma Holdings, Inc. reported 14 non-derivative transactions on 14 Forms 3, 4 and 5: 0 open-market purchases and 11 sales worth $2.1M.
- Transactions
- 14
- Purchases (P)
- 0
- Sales (S)
- 11
- Net shares, P minus S
- -249,998
- Insiders
- 5
- Last filed
- 2026-09-29
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| McCulloch Kevin | Officer · See Remarks | 5 | 0 | 4 |
| Pieper Steven | Officer · See Remarks | 4 | 0 | 4 |
| Hecht Beth | Officer · See Remarks | 3 | 0 | 3 |
| Shannon John Patrick Jr | Director, Officer · See Remarks | 1 | 0 | 0 |
| Kreher Nerissa | Director | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-28 | McCulloch Kevin | S (D) | 25,000 | $10 | 1,614,208 | Form 4 |
| 2026-09-01 | Hecht Beth | S (D) | 16,666 | $8.49 | 1,127,796 | Form 4 |
| 2026-09-01 | Pieper Steven | S (D) | 5,000 | $8.5 | 1,356,053 | Form 4 |
| 2026-09-01 | McCulloch Kevin | S (D) | 15,000 | $8.49 | 1,639,208 | Form 4 |
| 2026-08-12 | Pieper Steven | S (D) | 5,000 | $8.5 | 1,361,053 | Form 4 |
| 2026-08-03 | Hecht Beth | S (D) | 16,666 | $8.01 | 1,144,462 | Form 4 |
| 2026-08-03 | McCulloch Kevin | S (D) | 15,000 | $8.02 | 1,676,126 | Form 4 |
| 2026-08-01 | McCulloch Kevin | F (D) | 21,918 | $8.08 | 1,654,208 | Form 4 |
| 2026-08-01 | Shannon John Patrick Jr | F (D) | 36,645 | $8.08 | 2,898,933 | Form 4 |
| 2026-07-07 | Pieper Steven | S (D) | 27,600 | $8.52 | 1,366,053 | Form 4 |
| 2026-07-06 | Pieper Steven | S (D) | 17,400 | $8.5 | 1,393,653 | Form 4 |
| 2026-07-01 | Hecht Beth | S (D) | 16,666 | $8.03 | 1,161,128 | Form 4 |
| 2026-07-01 | Kreher Nerissa | A (A) | 33,582 | $0 | 33,582 | Form 4 |
| 2026-07-01 | McCulloch Kevin | S (D) | 90,000 | $8.03 | 1,691,126 | Form 4 |
Transaction codes in this quarter
Get XERS insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1867096&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · XERS company page · Xeris Biopharma Holdings, Inc. on SEC.gov
Questions
Are insiders buying or selling Xeris Biopharma Holdings, Inc. (XERS)?
In Q3 2026, insiders at Xeris Biopharma Holdings, Inc. reported 14 non-derivative transactions on 14 Forms 3, 4 and 5: 0 open-market purchases and 11 sales worth $2.1M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Xeris Biopharma Holdings, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/xers.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.